RNA Drugs Market Report

Europe RNA Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 26, 2020
  • PAGES：158
  • REPORT CODE：GMM586669
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The RNA Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.8% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe RNA Drugs Market Segmentations:

    By Player:

    • Arrowhead Pharmaceuticals

    • Silence Therapeutics

    • Calimmune Inc

    • Quark

    • Silenseed

    • Abbott Laboratories

    • Benitec Biopharma

    • Alnylam Pharmaceuticals

    • Roche

    • Dicerna

    • Gradalis

    • Senesco

    • RXi

    • Sanofi-Aventis

    • Pfizer

    • Tekmira

    By Type:

    • siRNA

    • ASO

    • miRNA

    • Nucleic Acid Aptamers

    By End-User:

    • Cancer

    • Diabetes

    • Tuberculosis

    • Cardiovascular Diseases

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of RNA Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe RNA Drugs Market Size and Growth Rate of siRNA from 2014 to 2026

    • 1.3.2 Europe RNA Drugs Market Size and Growth Rate of ASO from 2014 to 2026

    • 1.3.3 Europe RNA Drugs Market Size and Growth Rate of miRNA from 2014 to 2026

    • 1.3.4 Europe RNA Drugs Market Size and Growth Rate of Nucleic Acid Aptamers from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe RNA Drugs Market Size and Growth Rate of Cancer from 2014 to 2026

    • 1.4.2 Europe RNA Drugs Market Size and Growth Rate of Diabetes from 2014 to 2026

    • 1.4.3 Europe RNA Drugs Market Size and Growth Rate of Tuberculosis from 2014 to 2026

    • 1.4.4 Europe RNA Drugs Market Size and Growth Rate of Cardiovascular Diseases from 2014 to 2026

    • 1.4.5 Europe RNA Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of RNA Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of RNA Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of siRNA

      • 3.4.2 Market Size and Growth Rate of ASO

      • 3.4.3 Market Size and Growth Rate of miRNA

      • 3.4.4 Market Size and Growth Rate of Nucleic Acid Aptamers

    4 Segmentation of RNA Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of RNA Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Cancer for Construction

      • 4.4.2 Market Size and Growth Rate of Diabetes for Construction

      • 4.4.3 Market Size and Growth Rate of Tuberculosis for Construction

      • 4.4.4 Market Size and Growth Rate of Cardiovascular Diseases for Construction

      • 4.4.5 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe RNA Drugs Production Analysis by Top Regions

    • 5.2 Europe RNA Drugs Consumption Analysis by Top Regions

    • 5.3 Europe RNA Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of RNA Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in RNA Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in RNA Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in RNA Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in RNA Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in RNA Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in RNA Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany RNA Drugs Landscape Analysis

    • 7.1 Germany RNA Drugs Landscape Analysis by Major Types

    • 7.2 Germany RNA Drugs Landscape Analysis by Major End-Users

    8. UK RNA Drugs Landscape Analysis

    • 8.1 UK RNA Drugs Landscape Analysis by Major Types

    • 8.2 UK RNA Drugs Landscape Analysis by Major End-Users

    9. France RNA Drugs Landscape Analysis

    • 9.1 France RNA Drugs Landscape Analysis by Major Types

    • 9.2 France RNA Drugs Landscape Analysis by Major End-Users

    10. Italy RNA Drugs Landscape Analysis

    • 10.1 Italy RNA Drugs Landscape Analysis by Major Types

    • 10.2 Italy RNA Drugs Landscape Analysis by Major End-Users

    11. Spain RNA Drugs Landscape Analysis

    • 11.1 Spain RNA Drugs Landscape Analysis by Major Types

    • 11.2 Spain RNA Drugs Landscape Analysis by Major End-Users

    12. Poland RNA Drugs Landscape Analysis

    • 12.1 Poland RNA Drugs Landscape Analysis by Major Types

    • 12.2 Poland RNA Drugs Landscape Analysis by Major End-Users

    13. Russia RNA Drugs Landscape Analysis

    • 13.1 Russia RNA Drugs Landscape Analysis by Major Types

    • 13.2 Russia RNA Drugs Landscape Analysis by Major End-Users

    14. Switzerland RNA Drugs Landscape Analysis

    • 14.1 Switzerland RNA Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland RNA Drugs Landscape Analysis by Major End-Users

    15. Turkey RNA Drugs Landscape Analysis

    • 15.1 Turkey RNA Drugs Landscape Analysis by Major Types

    • 15.2 Turkey RNA Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark RNA Drugs Market Volume and Growth Rate

      • 16.3.2 Finland RNA Drugs Market Volume and Growth Rate

      • 16.3.3 Norway RNA Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden RNA Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland RNA Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium RNA Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands RNA Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg RNA Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia RNA Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia RNA Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania RNA Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Arrowhead Pharmaceuticals

      • 19.1.1 Arrowhead Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Silence Therapeutics

      • 19.2.1 Silence Therapeutics Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Calimmune Inc

      • 19.3.1 Calimmune Inc Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Quark

      • 19.4.1 Quark Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Silenseed

      • 19.5.1 Silenseed Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Abbott Laboratories

      • 19.6.1 Abbott Laboratories Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Benitec Biopharma

      • 19.7.1 Benitec Biopharma Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Alnylam Pharmaceuticals

      • 19.8.1 Alnylam Pharmaceuticals Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Roche

      • 19.9.1 Roche Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Dicerna

      • 19.10.1 Dicerna Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Gradalis

      • 19.11.1 Gradalis Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Senesco

      • 19.12.1 Senesco Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 RXi

      • 19.13.1 RXi Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Sanofi-Aventis

      • 19.14.1 Sanofi-Aventis Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Pfizer

      • 19.15.1 Pfizer Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Tekmira

      • 19.16.1 Tekmira Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    The List of Tables and Figures (Totals 110 Figures and 134 Tables)

    • Figure Product Picture

    • Figure RNA Drugs Market Size and Growth Rate of siRNA Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of ASO Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of miRNA Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of Nucleic Acid Aptamers Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of Cancer from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Diabetes from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Tuberculosis from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Cardiovascular Diseases from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania RNA Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of RNA Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of RNA Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of RNA Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of RNA Drugs by Different Types from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of siRNA Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of ASO Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of miRNA Market, 2015 - 2026 (USD Million)

    • Figure RNA Drugs Market Size and Growth Rate of Nucleic Acid Aptamers Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of RNA Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of RNA Drugs by Different End-Users from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Cancer from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Diabetes from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Tuberculosis from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Cardiovascular Diseases from 2014 to 2026

    • Figure RNA Drugs Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe RNA Drugs Production by Major Regions

    • Table Europe RNA Drugs Production Share by Major Regions

    • Figure Europe RNA Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe RNA Drugs Consumption by Major Regions

    • Table Europe RNA Drugs Consumption Share by Major Regions

    • Table Germany RNA Drugs Production, Import, Consumption and Export Analysis

    • Table UK RNA Drugs Production, Import, Consumption and Export Analysis

    • Table France RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Italy RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Spain RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Poland RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Russia RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in RNA Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in RNA Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in RNA Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in RNA Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany RNA Drugs Consumption by Types from 2014 to 2026

    • Table Germany RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK RNA Drugs Consumption by Types from 2014 to 2026

    • Table UK RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table UK RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table UK RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France RNA Drugs Consumption by Types from 2014 to 2026

    • Table France RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table France RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table France RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy RNA Drugs Consumption by Types from 2014 to 2026

    • Table Italy RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain RNA Drugs Consumption by Types from 2014 to 2026

    • Table Spain RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland RNA Drugs Consumption by Types from 2014 to 2026

    • Table Poland RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia RNA Drugs Consumption by Types from 2014 to 2026

    • Table Russia RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland RNA Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey RNA Drugs Consumption by Types from 2014 to 2026

    • Table Turkey RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNA Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNA Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNA Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries RNA Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Arrowhead Pharmaceuticals Profiles

    • Table Arrowhead Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Arrowhead Pharmaceuticals Product benchmarking

    • Table Arrowhead Pharmaceuticals Strategic initiatives

    • Table Arrowhead Pharmaceuticals SWOT analysis

    • Table Silence Therapeutics Profiles

    • Table Silence Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Silence Therapeutics Product benchmarking

    • Table Silence Therapeutics Strategic initiatives

    • Table Silence Therapeutics SWOT analysis

    • Table Calimmune Inc Profiles

    • Table Calimmune Inc Production, Value, Price, Gross Margin 2014-2019

    • Table Calimmune Inc Product benchmarking

    • Table Calimmune Inc Strategic initiatives

    • Table Calimmune Inc SWOT analysis

    • Table Quark Profiles

    • Table Quark Production, Value, Price, Gross Margin 2014-2019

    • Table Quark Product benchmarking

    • Table Quark Strategic initiatives

    • Table Quark SWOT analysis

    • Table Silenseed Profiles

    • Table Silenseed Production, Value, Price, Gross Margin 2014-2019

    • Table Silenseed Product benchmarking

    • Table Silenseed Strategic initiatives

    • Table Silenseed SWOT analysis

    • Table Abbott Laboratories Profiles

    • Table Abbott Laboratories Production, Value, Price, Gross Margin 2014-2019

    • Table Abbott Laboratories Product benchmarking

    • Table Abbott Laboratories Strategic initiatives

    • Table Abbott Laboratories SWOT analysis

    • Table Benitec Biopharma Profiles

    • Table Benitec Biopharma Production, Value, Price, Gross Margin 2014-2019

    • Table Benitec Biopharma Product benchmarking

    • Table Benitec Biopharma Strategic initiatives

    • Table Benitec Biopharma SWOT analysis

    • Table Alnylam Pharmaceuticals Profiles

    • Table Alnylam Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Alnylam Pharmaceuticals Product benchmarking

    • Table Alnylam Pharmaceuticals Strategic initiatives

    • Table Alnylam Pharmaceuticals SWOT analysis

    • Table Roche Profiles

    • Table Roche Production, Value, Price, Gross Margin 2014-2019

    • Table Roche Product benchmarking

    • Table Roche Strategic initiatives

    • Table Roche SWOT analysis

    • Table Dicerna Profiles

    • Table Dicerna Production, Value, Price, Gross Margin 2014-2019

    • Table Dicerna Product benchmarking

    • Table Dicerna Strategic initiatives

    • Table Dicerna SWOT analysis

    • Table Gradalis Profiles

    • Table Gradalis Production, Value, Price, Gross Margin 2014-2019

    • Table Gradalis Product benchmarking

    • Table Gradalis Strategic initiatives

    • Table Gradalis SWOT analysis

    • Table Senesco Profiles

    • Table Senesco Production, Value, Price, Gross Margin 2014-2019

    • Table Senesco Product benchmarking

    • Table Senesco Strategic initiatives

    • Table Senesco SWOT analysis

    • Table RXi Profiles

    • Table RXi Production, Value, Price, Gross Margin 2014-2019

    • Table RXi Product benchmarking

    • Table RXi Strategic initiatives

    • Table RXi SWOT analysis

    • Table Sanofi-Aventis Profiles

    • Table Sanofi-Aventis Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi-Aventis Product benchmarking

    • Table Sanofi-Aventis Strategic initiatives

    • Table Sanofi-Aventis SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

    • Table Tekmira Profiles

    • Table Tekmira Production, Value, Price, Gross Margin 2014-2019

    • Table Tekmira Product benchmarking

    • Table Tekmira Strategic initiatives

    • Table Tekmira SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US